Market Cap (In USD)
16.15 Million
Revenue (In USD)
-
Net Income (In USD)
-45.7 Million
Avg. Volume
2.37 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.44-5.83
- PE
- -0.35
- EPS
- -0.78
- Beta Value
- 1.249
- ISIN
- US28623U1016
- CUSIP
- 28623U101
- CIK
- 1783032
- Shares
- 59215800.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Joseph J. Ferra Jr.
- Employee Count
- -
- Website
- https://elevationoncology.com
- Ipo Date
- 2021-06-25
- Details
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
More Stocks
-
THCOM
-
HOVSHOV Services Limited
HOVS
-
TIPH
-
601952
-
VIH
-
603028
-
AIRRFAurion Resources Ltd.
AIRRF
-
FRMEP